Parallax Health Sciences, Inc.
PRLX
Other OTC0.00
USD
- -
- -
CIK
0001388410
ISIN
US69916A1051
CUSIP
69916A105
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Paul R. Arena
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 1327 Ocean Avenue Santa Monica CA United States of America 90401
- IPO Date
- Jan 24, 2022
- CIK
- 0001388410
- Website
- parallaxhealthsciences.com
- Similar Companies
- Business
- Parallax Health Sciences, Inc. is an integrated digital healthcare company that designs, develops, and delivers scalable connected products, services, and actionable data to enable remote communication, diagnosis, treatment, and monitoring of patients. Its core offerings include telehealth management solutions, patient point-of-care testing and diagnostics, mobile phone applications interoperable across operating systems, and cloud-based data analytics enabling healthcare providers and patients to manage health outcomes effectively. The company's main products encompass FDA-approved diagnostic testing platforms, remote patient monitoring applications, and telehealth communication tools focused on improving patient compliance, disease management, and cost-effective healthcare delivery primarily in the United States. Founded in 2005 and headquartered in Beverly Hills, California, Parallax Health Sciences operates primarily in the healthcare technology and telemedicine sectors. In the last 1-2 years, Parallax Health Sciences has pursued strategic alliances and expanded its diagnostics and telehealth offerings. Notably, it has launched patented telehealth initiatives to enhance communication between healthcare providers and patients, aimed at reducing emergency room admissions. The company also secured federal contracts and agreements for the distribution of COVID-19 testing kits and personal protective equipment (PPE) during the early phase of the pandemic. Despite regulatory challenges and SEC charges in 2020 concerning the accuracy of its COVID-19 related claims, Parallax has continued to develop its FDA-approved diagnostic platforms and telehealth management applications. It recently formed partnerships to distribute individually sealed pharmaceuticals and extended acquisition agreements to grow its product and customer base. Parallax Health Sciences targets healthcare providers, patients in need of remote health management, and institutional clients requiring diagnostic and telehealth solutions. Its business focus spans digital health transformation with outcome-driven technology solutions in the United States. The company emphasizes interoperable software systems and data analytics that support patient-centered care and expanded accessibility of medical diagnostics through telehealth channels. Parallax Health Sciences was formerly known as Endeavor Power Corporation before a name change in 2014 and continues to build on its foundation in healthcare innovation and digital technology integration.